Search Results - "Samson, M K"

Efficacy of MGI 114 (6-hydroxymethylacylfulvene, HMAF) against the mdr1/gp170 metastatic MV522 lung carcinoma xenograft by Kelner, M.J, McMorris, T.C, Estes, L, Samson, K.M, Bagnell, R.D, Taetle, R

“…Illudins are a novel class of agents with a chemical structure entirely different from current chemotherapeutic agents. A new semisynthetic derivative, MGI 114…”
Get full text

Anti-leukemic action of the novel agent MGI 114 (HMAF) and synergistic action with topotecan by KELNER, M. J, MCMORRIS, T. C, ESTES, L, SAMSON, K. M, TRANI, N. A, MACDONALD, J. R

“…The illudin derivative MGI 114 (6-hydroxymethylacylfulvene or HMAF) is currently in phase II chemotherapeutic clinical trials for a variety of solid tumors…”
Get full text

The role of physician-assistants in critical care units by Dubaybo, B A, Samson, M K, Carlson, R W

“…We evaluated the feasibility of utilizing physician assistants as providers of primary care in a medical ICU. After a three-month period of rigorous training,…”
Get more information

Efficacy of HMAF (MGI-114) in the MV522 metastatic lung carcinoma xenograft model nonresponsive to traditional anticancer agents by KELNER, M. J, MCMORRIS, T. C, ESTES, L, WANG, W, SAMSON, K. M, TAETLE, R

“…Illudin analogs are cytotoxic to a variety of multidrug resistant cell lines, and display an unusual toxicity towards DNA helicase-deficient cell lines…”
Get full text

Characterization of MGI 114 (HMAF) histiospecific toxicity in human tumor cell lines by KELNER, M. J, MCMORRIS, T. C, MONTOYA, M. A, ESTES, L, UGLIK, S. F, RUTHERFORD, M, SAMSON, K. M, BAGNELL, R. D, TAETLE, R

“…The acylfulvenes are a class of antitumor agents derived from the fungal toxin illudin S. One acylfulvene derivative, MGI 114 (HMAF), demonstrates marked…”
Get full text

Characterization of cellular accumulation and toxicity of illudin S in sensitive and nonsensitive tumor cells by KELNER, M. J, MCMORRIS, T. C, MONTOYA, M. A, ESTES, L, RUTHERFORD, M, SAMSON, K. M, TAETLE, R

“…Illudins are novel low molecular weight natural products cytotoxic to human tumor cells in vitro. Illudin-derived analogs are effective against experimental…”
Get full text

Randomized comparison of cyclophosphamide, imidazole carboxamide, and adriamycin versus cyclophosphamide and adriamycin in patients with advanced stage malignant mesothelioma: a Sarcoma Intergroup Study by Samson, M K, Wasser, L P, Borden, E C, Wanebo, H J, Creech, R H, Phillips, M, Baker, L H

“…In 1980, a consensus chemotherapy intergroup study for advanced malignant mesothelioma was initiated based on a collaborative agreement among the Eastern…”
Get more information

Characterization of acylfulvene histiospecific toxicity in human tumor cell lines by KELNER, M. J, MCMORRIS, T. C, MONTOYA, M. A, ESTES, L, UGLIK, S. F, RUTHERFORD, M, SAMSON, K. M, BAGNELL, R. D, TAETLE, R

“…Acylfulvene derivatives demonstrate marked efficacy in xenograft carcinoma models as compared with the parent illudin compounds. To elucidate the increased…”
Get full text

Dose-response and dose-survival advantage for high versus low-dose cisplatin combined with vinblastine and bleomycin in disseminated testicular cancer. A Southwest Oncology Group study by Samson, M K, Rivkin, S E, Jones, S E, Costanzi, J J, LoBuglio, A F, Stephens, R L, Gehan, E A, Cummings, G D

“…One-hundred fourteen patients with advanced testicular cancer were randomized to treatment consisting of either high-dose (120 mg/m2, monthly) or low-dose (15…”
Get more information

A randomized trial of cisplatin, vinblastine, and bleomycin versus vinblastine, cisplatin, and etoposide in the treatment of advanced germ cell tumors of the testis: a Southwest Oncology Group study by Wozniak, A J, Samson, M K, Shah, N T, Crawford, E D, Ford, C D, Altman, S J, Stephens, R L, Natale, R B, Bouroncle, B A, Blumenstein, B A

“…This is a Southwest Oncology Group (SWOG) prospective randomized trial of cisplatin, vinblastine, and bleomycin (PVB) versus vinblastine, cisplatin, and…”
Get more information

Fludarabine phosphate. Phase II evaluation in advanced soft-tissue sarcomas by Pazdur, R, Samson, M K, Baker, L H

“…Fludarabine phosphate (NSC-312878) was administered to 23 patients with advanced soft-tissue sarcomas. Patients entered on the study had a median performance…”
Get more information

CBDCA: phase II evaluation in advanced colorectal carcinoma by Pazdur, R, Samson, M K, Baker, L H

“…Carboplatin (CBDCA) (NSC-241240) was administered to 25 consecutive patients with measurable colorectal carcinomas. Twenty-four patients were previously…”
Get more information

Aclacinomycin A. Phase II evaluation in advanced soft tissue sarcoma by Pazdur, R, Samson, M K, Baker, L H

“…Aclacinomycin A (ACLA-A), an anthracycline antibiotic, was administered in a Phase II study to 20 patients with advanced, measurable soft tissue sarcomas. The…”
Get more information

Aclacinomycin A. Phase II evaluation in bronchogenic squamous-cell carcinoma by Pazdur, R, Samson, M K, Baker, L H

“…Aclacinomycin A (ACLA-A) was administered to 22 patients with metastatic measurable bronchogenic squamous-cell carcinoma in a Phase II trial of the drug…”
Get more information

Evaluation of amonafide in disseminated malignant melanoma : a Southwest Oncology Group study by SLAVIK, M, KOPECKY, K. J, SONDAK, V, CRAIG, J. B, SAMSON, M. K

“…Amonafide (AMF), NSC 308847 is an investigational anticancer drug acting as a DNA intercalating agent. This paper presents results of a phase II clinical study…”
Get full text

Phase II evaluation of aclacinomycin-A in patients with adenocarcinoma and large cell carcinoma of the lung by Tapazoglou, E, Haas, C D, Samson, M K, Baker, L H, Pazdur, R

“…Aclacinomycin-A (ACLA-A), the new anthracycline antibiotic that produces substantially less cardiotoxicity relative to doxorubicin, was evaluated in a phase II…”
Get more information

Phase I evaluation and clinical pharmacology of tricyclic nucleoside 5'-phosphate using a weekly intravenous regimen by SCHILCHER, R. B, HAAS, C. D, SAMSON, M. K, YOUNG, J. D, BAKER, L. H

“…Tricyclic nucleoside phosphate (TCN-P) was selected for clinical trials because of its unusual chemical structure and activity against L1210 murine leukemia…”
Get full text

Evaluation of fludarabine phosphate in malignant melanoma : a southwest oncology group study by KISH, J. A, KOPECKY, K, SAMSON, M. K, VON HOFF, D. D, FLETCHER, W. S, KEMPF, R. A, MUGGIA, F. M

“…Twenty-seven evaluable patients with advanced malignant melanoma received fludarabine phosphate in a daily x 5 injection. Initial dosing was based on the…”
Get full text

Efficacy of Acylfulvene Illudin analogues against a metastatic lung carcinoma MV522 xenograft nonresponsive to traditional anticancer agents: retention of activity against various mdr phenotypes and unusual cytotoxicity against ERCC2 and ERCC3 DNA helicase-deficient cells by Kelner, M J, McMorris, T C, Estes, L, Starr, R J, Rutherford, M, Montoya, M, Samson, K M, Taetle, R

“…Four second-generation Illudin analogues were synthesized and tested for antitumor activity using a metastatic lung carcinoma xenograft model resistant to…”
Get full text

Phase II clinical evaluation of AZQ in adenocarcinoma of the lung by Decker, D A, Samson, M K, Haas, C D, Baker, L H

“…Twenty patients with advanced measurable adenocarcinoma of the lung were treated with AZQ 20 mg/m2 weekly for 4 weeks, followed by a 2-week rest. No complete…”
Get more information